Tag: GlobeNewswire

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) — EXL [NASDAQ: EXLS], a global data and AI company, announced that it has been recognized as Leader and Star Performer in the Everest Group Customer Experience Management (CXM) PEAK Matrix Assessment – Americas 2026 report.

The Everest Group report evaluated 63 leading customer experience management providers on their ability to meet enterprise needs and deliver scalable, secure and high-impact CXM solutions through AI-enabled operations, domain expertise, operational resilience, and proven execution capabilities. EXL was recognized as a Leader and Star Performer for its deep domain experience, speed and flexibility of solutions, and strength in customer experience transformation. EXL advanced its standing from a Major Contributor in the 2025 report to a Leader and Star Performer in 2026.

“EXL has emerged as a Leader and Star Performer in Everest Group’s Customer Experience Management (CXM) Services PEAK Matrix® Assessment 2026 – Americas, supported by strong growth in its overall and digital CXM business, deeper penetration across healthcare, e-commerce, retail and distribution and increasing traction for transformation-led engagements,” said Chhandak Biswas, vice president, Everest Group. “Its EXL Customer Experience Suite, including CX proprietary IP, strengthens its ability to combine interaction intelligence, journey redesign, conversational AI and observability with broader CX advisory and implementation capabilities. Its strong buyer recognition for execution and CX transformation, further supports its move from a Major Contender to a Leader.”

The report cited EXL’s ability to deliver strong client outcomes through customer experience transformation, strategic partnerships, and flexible execution models. The report also highlighted EXL’s investments in AI-enabled CX capabilities, analytics, automation, and proprietary technologies that help organizations improve customer experiences, enhance operational performance, and achieve measurable business results.

“We’re proud to earn this Leader and Star Performer designation and, in the process, help our clients meet their new challenges and deliver better CX, said Shashank Verma, senior vice president and global head of customer service transformation at EXL. “Customer experience is shifting from standalone AI tools to human-integrated AI and agentic workflow, with a greater emphasis on governance and measurable outcomes.”

Read the Everest Group 2026 report and learn how EXL is helping organizations navigate the next generation of customer experience. For more information about EXL’s AI solutions, click here.

About EXL

EXL (NASDAQ: EXLS) is a global data and AI company that offers services and solutions to reinvent client business models, drive better outcomes and unlock growth with speed. EXL propels enterprises to go beyond AI ambition to impact by combining the power of data, AI, and deep industry context with trusted execution. Our clients include the world’s leading corporations across insurance, healthcare, banking and capital markets, retail, communications and media, and energy and infrastructure, among others. EXL was founded in 1999 with the core values of innovation, collaboration, excellence, integrity and respect. We are headquartered in New York and have over 74,000 employees spanning six continents. For more information, visit http://www.exlservice.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to EXL’s operations and business environment, all of which are difficult to predict and many of which are beyond EXL’s control. Forward-looking statements include information concerning EXL’s possible or assumed future results of operations, including descriptions of its business strategy. These statements may include words such as “may,” “will,” “should,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions. These statements are based on assumptions that we have made in light of management’s experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although EXL believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect EXL’s actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors, which include our ability to maintain and grow client demand, our ability to hire and retain sufficiently trained employees, and our ability to accurately estimate and/or manage costs, rising interest rates, rising inflation and recessionary economic trends, are discussed in more detail in EXL’s filings with the Securities and Exchange Commission, including EXL’s Annual Report on Form 10-K. You should keep in mind that any forward-looking statement made herein, or elsewhere, speaks only as of the date on which it is made. New risks and uncertainties come up from time to time, and it is impossible to predict these events or how they may affect EXL. EXL has no obligation to update any forward-looking statements after the date hereof, except as required by federal securities laws.

Contact:
Keith Little
Head of Public Relations
media.relations@exlservice.com  

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) — EXL [NASDAQ: EXLS], a global data and AI company, announced that it has been recognized as Leader and Star Performer in the Everest Group Customer Experience Management (CXM) PEAK Matrix Assessment – Americas 2026 report.

The Everest Group report evaluated 63 leading customer experience management providers on their ability to meet enterprise needs and deliver scalable, secure and high-impact CXM solutions through AI-enabled operations, domain expertise, operational resilience, and proven execution capabilities. EXL was recognized as a Leader and Star Performer for its deep domain experience, speed and flexibility of solutions, and strength in customer experience transformation. EXL advanced its standing from a Major Contributor in the 2025 report to a Leader and Star Performer in 2026.

“EXL has emerged as a Leader and Star Performer in Everest Group’s Customer Experience Management (CXM) Services PEAK Matrix® Assessment 2026 – Americas, supported by strong growth in its overall and digital CXM business, deeper penetration across healthcare, e-commerce, retail and distribution and increasing traction for transformation-led engagements,” said Chhandak Biswas, vice president, Everest Group. “Its EXL Customer Experience Suite, including CX proprietary IP, strengthens its ability to combine interaction intelligence, journey redesign, conversational AI and observability with broader CX advisory and implementation capabilities. Its strong buyer recognition for execution and CX transformation, further supports its move from a Major Contender to a Leader.”

The report cited EXL’s ability to deliver strong client outcomes through customer experience transformation, strategic partnerships, and flexible execution models. The report also highlighted EXL’s investments in AI-enabled CX capabilities, analytics, automation, and proprietary technologies that help organizations improve customer experiences, enhance operational performance, and achieve measurable business results.

“We’re proud to earn this Leader and Star Performer designation and, in the process, help our clients meet their new challenges and deliver better CX, said Shashank Verma, senior vice president and global head of customer service transformation at EXL. “Customer experience is shifting from standalone AI tools to human-integrated AI and agentic workflow, with a greater emphasis on governance and measurable outcomes.”

Read the Everest Group 2026 report and learn how EXL is helping organizations navigate the next generation of customer experience. For more information about EXL’s AI solutions, click here.

About EXL

EXL (NASDAQ: EXLS) is a global data and AI company that offers services and solutions to reinvent client business models, drive better outcomes and unlock growth with speed. EXL propels enterprises to go beyond AI ambition to impact by combining the power of data, AI, and deep industry context with trusted execution. Our clients include the world’s leading corporations across insurance, healthcare, banking and capital markets, retail, communications and media, and energy and infrastructure, among others. EXL was founded in 1999 with the core values of innovation, collaboration, excellence, integrity and respect. We are headquartered in New York and have over 74,000 employees spanning six continents. For more information, visit http://www.exlservice.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to EXL’s operations and business environment, all of which are difficult to predict and many of which are beyond EXL’s control. Forward-looking statements include information concerning EXL’s possible or assumed future results of operations, including descriptions of its business strategy. These statements may include words such as “may,” “will,” “should,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions. These statements are based on assumptions that we have made in light of management’s experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although EXL believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect EXL’s actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors, which include our ability to maintain and grow client demand, our ability to hire and retain sufficiently trained employees, and our ability to accurately estimate and/or manage costs, rising interest rates, rising inflation and recessionary economic trends, are discussed in more detail in EXL’s filings with the Securities and Exchange Commission, including EXL’s Annual Report on Form 10-K. You should keep in mind that any forward-looking statement made herein, or elsewhere, speaks only as of the date on which it is made. New risks and uncertainties come up from time to time, and it is impossible to predict these events or how they may affect EXL. EXL has no obligation to update any forward-looking statements after the date hereof, except as required by federal securities laws.

Contact:
Keith Little
Head of Public Relations
media.relations@exlservice.com  

LAKE MARY, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) — OpenWorld, Inc. (NASDAQ: OPNW) (“OpenWorld” or the “Company”), a digital assets and blockchain technology company focused on the tokenization of real-world assets, today announced that it expects to release financial results for the third quarter ended September 30, 2026, after the market close on Thursday, November 12, 2026, and host a conference call and simultaneous webcast at 4:30 p.m. ET that day. The Company expects to file its Quarterly Report on Form 10-Q with the Securities and Exchange Commission on Friday, November 13, 2026, after the market close. During the conference call and webcast, Matthew Shaw, Chairman and Chief Executive Officer, Russel McMeekin, President, and Gerard Hernandez, Chief Financial Officer, will review the results and provide a business update, followed by a question-and-answer session.

The third quarter financial results will primarily reflect the operating results of legacy OpenWorld, the accounting acquirer in the reverse takeover transaction with VerifyMe, Inc. (“VerifyMe”) completed on September 30, 2026. The Company’s September 30, 2026 consolidated balance sheet will reflect the combined entity, while its third quarter operating results will not include VerifyMe’s pre-transaction operating results.

To listen to the audio-only webcast, please use the following link: webcast link. If you would like to participate and ask questions during the call, please register here: registration link. After registering, you will receive an email with dial-in details along with a unique access code required to join the live call.

A replay of the webcast will be available on the Investors section of the Company’s website at Investors | OpenWorld following the call.

Investors and analysts may submit questions in advance to OpenWorldIR@allianceadvisors.com.

About OpenWorld

OpenWorld, Inc. (NASDAQ: OPNW) is a digital assets and blockchain technology company. Through its OpenWorld Enterprise platform, the Company provides financial structuring and blockchain infrastructure for the issuance and distribution of tokenized real-world assets to institutional and retail investors. To learn more, visit openworld.dev.

Contacts

Investors: OpenWorldIR@allianceadvisors.com

Media: Aayushi@allianceadvisors.com

LAKE MARY, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) — OpenWorld, Inc. (NASDAQ: OPNW) (“OpenWorld” or the “Company”), a digital assets and blockchain technology company focused on the tokenization of real-world assets, today announced that it expects to release financial results for the third quarter ended September 30, 2026, after the market close on Thursday, November 12, 2026, and host a conference call and simultaneous webcast at 4:30 p.m. ET that day. The Company expects to file its Quarterly Report on Form 10-Q with the Securities and Exchange Commission on Friday, November 13, 2026, after the market close. During the conference call and webcast, Matthew Shaw, Chairman and Chief Executive Officer, Russel McMeekin, President, and Gerard Hernandez, Chief Financial Officer, will review the results and provide a business update, followed by a question-and-answer session.

The third quarter financial results will primarily reflect the operating results of legacy OpenWorld, the accounting acquirer in the reverse takeover transaction with VerifyMe, Inc. (“VerifyMe”) completed on September 30, 2026. The Company’s September 30, 2026 consolidated balance sheet will reflect the combined entity, while its third quarter operating results will not include VerifyMe’s pre-transaction operating results.

To listen to the audio-only webcast, please use the following link: webcast link. If you would like to participate and ask questions during the call, please register here: registration link. After registering, you will receive an email with dial-in details along with a unique access code required to join the live call.

A replay of the webcast will be available on the Investors section of the Company’s website at Investors | OpenWorld following the call.

Investors and analysts may submit questions in advance to OpenWorldIR@allianceadvisors.com.

About OpenWorld

OpenWorld, Inc. (NASDAQ: OPNW) is a digital assets and blockchain technology company. Through its OpenWorld Enterprise platform, the Company provides financial structuring and blockchain infrastructure for the issuance and distribution of tokenized real-world assets to institutional and retail investors. To learn more, visit openworld.dev.

Contacts

Investors: OpenWorldIR@allianceadvisors.com

Media: Aayushi@allianceadvisors.com

LAKE MARY, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) — OpenWorld, Inc. (NASDAQ: OPNW) (“OpenWorld” or the “Company”), a digital assets and blockchain technology company focused on the tokenization of real-world assets, today announced that it expects to release financial results for the third quarter ended September 30, 2026, after the market close on Thursday, November 12, 2026, and host a conference call and simultaneous webcast at 4:30 p.m. ET that day. The Company expects to file its Quarterly Report on Form 10-Q with the Securities and Exchange Commission on Friday, November 13, 2026, after the market close. During the conference call and webcast, Matthew Shaw, Chairman and Chief Executive Officer, Russel McMeekin, President, and Gerard Hernandez, Chief Financial Officer, will review the results and provide a business update, followed by a question-and-answer session.

The third quarter financial results will primarily reflect the operating results of legacy OpenWorld, the accounting acquirer in the reverse takeover transaction with VerifyMe, Inc. (“VerifyMe”) completed on September 30, 2026. The Company’s September 30, 2026 consolidated balance sheet will reflect the combined entity, while its third quarter operating results will not include VerifyMe’s pre-transaction operating results.

To listen to the audio-only webcast, please use the following link: webcast link. If you would like to participate and ask questions during the call, please register here: registration link. After registering, you will receive an email with dial-in details along with a unique access code required to join the live call.

A replay of the webcast will be available on the Investors section of the Company’s website at Investors | OpenWorld following the call.

Investors and analysts may submit questions in advance to OpenWorldIR@allianceadvisors.com.

About OpenWorld

OpenWorld, Inc. (NASDAQ: OPNW) is a digital assets and blockchain technology company. Through its OpenWorld Enterprise platform, the Company provides financial structuring and blockchain infrastructure for the issuance and distribution of tokenized real-world assets to institutional and retail investors. To learn more, visit openworld.dev.

Contacts

Investors: OpenWorldIR@allianceadvisors.com

Media: Aayushi@allianceadvisors.com

Kennewick, WA, Nov. 03, 2026 (GLOBE NEWSWIRE) — Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy^™ (PRnT) for the treatment of cancerous tumors, is pleased to announce continued expansion of its IsoPet^® Animal Cancer Division, with four additional veterinary facilities advancing through the certification, licensing, and onboarding process to offer IsoPet^® cancer treatment.

The expansion represents an important step in Vivos’ strategy to broaden access to its innovative cancer therapy for animals while building the clinical infrastructure necessary to support increased treatment volumes, recurring product demand, and long-term revenue growth.

Four Veterinary Facilities Advancing Toward IsoPet^® Certification

Veterinary Specialist Partners – Louisville, Kentucky

Led by co-founders Dr. Grace Clark and Dr. Scott Rizzo, both Doctors of Veterinary Medicine and Diplomates of the American College of Veterinary Internal Medicine, Veterinary Specialist Partners is an established specialty veterinary hospital offering advanced diagnostic, internal medicine, and oncology services. The addition of IsoPet^® would complement the hospital’s existing capabilities and expand treatment options for companion animals facing challenging cancer diagnoses.

Grace Veterinary Hospital – Sherrills Ford, North Carolina

Under the leadership of Dr. Jean Tuttle, Grace Veterinary Hospital provides comprehensive veterinary medicine, rehabilitation, and patient-centered care. The hospital is progressing through IsoPet^® training and onboarding, positioning the facility to introduce an additional localized cancer treatment option for pets throughout North Carolina and surrounding communities.

Malibu Coast Animal Hospital – Malibu, California

Founded by Dr. Dean Graulich, Malibu Coast Animal Hospital is an established veterinary practice offering comprehensive medical and surgical services. The hospital is advancing through California’s radioactive materials licensing process and is positioned to become Vivos’ first IsoPet^® certified clinic in the state, representing an important opportunity to expand access to treatment on the West Coast.

Palm Beach Equine Clinic – Wellington, Florida

Led by board-certified equine surgeon Dr. Robert Brusie and his veterinary team, Palm Beach Equine Clinic is a recognized center for advanced equine medicine and surgery. The clinic is progressing through IsoPet^® certification preparations, expanding Vivos’ opportunity to serve the equine oncology market, including horses requiring treatment for solid tumors and other localized cancers.

Building a Scalable Network Through Comprehensive Certification and Training

Establishing an IsoPet^® certified veterinary facility requires a comprehensive process that extends well beyond a traditional clinic partnership. Because IsoPet^® utilizes Yttrium-90, a therapeutic radioisotope, each participating facility must meet applicable state radioactive materials licensing requirements, with regulatory review and approval timelines varying by jurisdiction.

In parallel with licensing, Vivos has implemented a structured certification and onboarding program designed to prepare veterinary teams for the safe, effective, and consistent administration of IsoPet^®. This process includes specialized radiation safety education, treatment protocol training, equipment preparation, practical application exercises, and coordinated support through the facility’s initial treatments.

While these regulatory and operational requirements take time, they are essential to establishing sustainable, revenue-generating treatment centers capable of delivering IsoPet^® consistently and safely. Each new clinic represents an investment in the Company’s long-term clinical network, with the potential to generate recurring product demand as treatment programs become established.

Vivos continues to work closely with its veterinary partners to advance each facility through the required milestones as efficiently as possible, while maintaining the standards necessary for regulatory compliance, clinical readiness, and quality patient care.

Expanding Clinical Adoption and Long-Term Commercial Opportunity

Vivos is also seeing increasing demand across its existing certified clinic network as more pet owners seek IsoPet^® treatment for their animals. This growing demand supports continued utilization at established clinics and reinforces the opportunity to expand access through new facilities.

The addition of these four facilities reflects growing interest in IsoPet^® among veterinary professionals and strengthens Vivos’ presence across multiple U.S. regions and veterinary specialties.

As participating clinics complete certification and begin treating patients, Vivos anticipates increased treatment capacity, broader geographic access, and additional opportunities for recurring IsoPet^® product sales.

With domestic IsoPet^® manufacturing capabilities established at the Company’s Applied Process Engineering Laboratory (APEL) in Richland, Washington, Vivos is building the production and clinical infrastructure necessary to support its expanding veterinary network. APEL is focused on reducing production costs to help Vivos reach break-even and advance toward profitability.

The Company’s focus remains on converting its growing clinic pipeline into fully operational treatment centers, increasing utilization across its certified network, and establishing IsoPet^® as a scalable, revenue-generating business within veterinary oncology.

The continued expansion of the IsoPet^® Animal Cancer Division supports Vivos’ broader strategy of growing commercial revenue while advancing its Precision Radionuclide Therapy^™ platform.

About Vivos Inc.

Vivos Inc. is developing advanced Yttrium-90-based Precision Radionuclide Therapy^™ (PRnT) treatments for tumors in both animals (IsoPet^®) and humans (RadioGel^®). The Company is committed to advancing targeted cancer therapies through precise, localized delivery of therapeutic radiation. IsoPet^® is commercially available for veterinary use through appropriately licensed and certified facilities in the United States.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of applicable securities laws. These statements include expectations regarding clinic certifications, regulatory approvals, future treatment activity, commercial expansion, and revenue growth. Actual results may differ materially from those expressed or implied due to regulatory timelines, operational requirements, market conditions, and other risks and uncertainties. Vivos Inc. undertakes no obligation to update forward-looking statements except as required by law.

Contact:
Vivos Inc. Investor Relations investors@vivosinc.com www.VivosInc.com

Kennewick, WA, Nov. 03, 2026 (GLOBE NEWSWIRE) — Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy^™ (PRnT) for the treatment of cancerous tumors, is pleased to announce continued expansion of its IsoPet^® Animal Cancer Division, with four additional veterinary facilities advancing through the certification, licensing, and onboarding process to offer IsoPet^® cancer treatment.

The expansion represents an important step in Vivos’ strategy to broaden access to its innovative cancer therapy for animals while building the clinical infrastructure necessary to support increased treatment volumes, recurring product demand, and long-term revenue growth.

Four Veterinary Facilities Advancing Toward IsoPet^® Certification

Veterinary Specialist Partners – Louisville, Kentucky

Led by co-founders Dr. Grace Clark and Dr. Scott Rizzo, both Doctors of Veterinary Medicine and Diplomates of the American College of Veterinary Internal Medicine, Veterinary Specialist Partners is an established specialty veterinary hospital offering advanced diagnostic, internal medicine, and oncology services. The addition of IsoPet^® would complement the hospital’s existing capabilities and expand treatment options for companion animals facing challenging cancer diagnoses.

Grace Veterinary Hospital – Sherrills Ford, North Carolina

Under the leadership of Dr. Jean Tuttle, Grace Veterinary Hospital provides comprehensive veterinary medicine, rehabilitation, and patient-centered care. The hospital is progressing through IsoPet^® training and onboarding, positioning the facility to introduce an additional localized cancer treatment option for pets throughout North Carolina and surrounding communities.

Malibu Coast Animal Hospital – Malibu, California

Founded by Dr. Dean Graulich, Malibu Coast Animal Hospital is an established veterinary practice offering comprehensive medical and surgical services. The hospital is advancing through California’s radioactive materials licensing process and is positioned to become Vivos’ first IsoPet^® certified clinic in the state, representing an important opportunity to expand access to treatment on the West Coast.

Palm Beach Equine Clinic – Wellington, Florida

Led by board-certified equine surgeon Dr. Robert Brusie and his veterinary team, Palm Beach Equine Clinic is a recognized center for advanced equine medicine and surgery. The clinic is progressing through IsoPet^® certification preparations, expanding Vivos’ opportunity to serve the equine oncology market, including horses requiring treatment for solid tumors and other localized cancers.

Building a Scalable Network Through Comprehensive Certification and Training

Establishing an IsoPet^® certified veterinary facility requires a comprehensive process that extends well beyond a traditional clinic partnership. Because IsoPet^® utilizes Yttrium-90, a therapeutic radioisotope, each participating facility must meet applicable state radioactive materials licensing requirements, with regulatory review and approval timelines varying by jurisdiction.

In parallel with licensing, Vivos has implemented a structured certification and onboarding program designed to prepare veterinary teams for the safe, effective, and consistent administration of IsoPet^®. This process includes specialized radiation safety education, treatment protocol training, equipment preparation, practical application exercises, and coordinated support through the facility’s initial treatments.

While these regulatory and operational requirements take time, they are essential to establishing sustainable, revenue-generating treatment centers capable of delivering IsoPet^® consistently and safely. Each new clinic represents an investment in the Company’s long-term clinical network, with the potential to generate recurring product demand as treatment programs become established.

Vivos continues to work closely with its veterinary partners to advance each facility through the required milestones as efficiently as possible, while maintaining the standards necessary for regulatory compliance, clinical readiness, and quality patient care.

Expanding Clinical Adoption and Long-Term Commercial Opportunity

Vivos is also seeing increasing demand across its existing certified clinic network as more pet owners seek IsoPet^® treatment for their animals. This growing demand supports continued utilization at established clinics and reinforces the opportunity to expand access through new facilities.

The addition of these four facilities reflects growing interest in IsoPet^® among veterinary professionals and strengthens Vivos’ presence across multiple U.S. regions and veterinary specialties.

As participating clinics complete certification and begin treating patients, Vivos anticipates increased treatment capacity, broader geographic access, and additional opportunities for recurring IsoPet^® product sales.

With domestic IsoPet^® manufacturing capabilities established at the Company’s Applied Process Engineering Laboratory (APEL) in Richland, Washington, Vivos is building the production and clinical infrastructure necessary to support its expanding veterinary network. APEL is focused on reducing production costs to help Vivos reach break-even and advance toward profitability.

The Company’s focus remains on converting its growing clinic pipeline into fully operational treatment centers, increasing utilization across its certified network, and establishing IsoPet^® as a scalable, revenue-generating business within veterinary oncology.

The continued expansion of the IsoPet^® Animal Cancer Division supports Vivos’ broader strategy of growing commercial revenue while advancing its Precision Radionuclide Therapy^™ platform.

About Vivos Inc.

Vivos Inc. is developing advanced Yttrium-90-based Precision Radionuclide Therapy^™ (PRnT) treatments for tumors in both animals (IsoPet^®) and humans (RadioGel^®). The Company is committed to advancing targeted cancer therapies through precise, localized delivery of therapeutic radiation. IsoPet^® is commercially available for veterinary use through appropriately licensed and certified facilities in the United States.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of applicable securities laws. These statements include expectations regarding clinic certifications, regulatory approvals, future treatment activity, commercial expansion, and revenue growth. Actual results may differ materially from those expressed or implied due to regulatory timelines, operational requirements, market conditions, and other risks and uncertainties. Vivos Inc. undertakes no obligation to update forward-looking statements except as required by law.

Contact:
Vivos Inc. Investor Relations investors@vivosinc.com www.VivosInc.com

Kennewick, WA, Nov. 03, 2026 (GLOBE NEWSWIRE) — Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy^™ (PRnT) for the treatment of cancerous tumors, is pleased to announce continued expansion of its IsoPet^® Animal Cancer Division, with four additional veterinary facilities advancing through the certification, licensing, and onboarding process to offer IsoPet^® cancer treatment.

The expansion represents an important step in Vivos’ strategy to broaden access to its innovative cancer therapy for animals while building the clinical infrastructure necessary to support increased treatment volumes, recurring product demand, and long-term revenue growth.

Four Veterinary Facilities Advancing Toward IsoPet^® Certification

Veterinary Specialist Partners – Louisville, Kentucky

Led by co-founders Dr. Grace Clark and Dr. Scott Rizzo, both Doctors of Veterinary Medicine and Diplomates of the American College of Veterinary Internal Medicine, Veterinary Specialist Partners is an established specialty veterinary hospital offering advanced diagnostic, internal medicine, and oncology services. The addition of IsoPet^® would complement the hospital’s existing capabilities and expand treatment options for companion animals facing challenging cancer diagnoses.

Grace Veterinary Hospital – Sherrills Ford, North Carolina

Under the leadership of Dr. Jean Tuttle, Grace Veterinary Hospital provides comprehensive veterinary medicine, rehabilitation, and patient-centered care. The hospital is progressing through IsoPet^® training and onboarding, positioning the facility to introduce an additional localized cancer treatment option for pets throughout North Carolina and surrounding communities.

Malibu Coast Animal Hospital – Malibu, California

Founded by Dr. Dean Graulich, Malibu Coast Animal Hospital is an established veterinary practice offering comprehensive medical and surgical services. The hospital is advancing through California’s radioactive materials licensing process and is positioned to become Vivos’ first IsoPet^® certified clinic in the state, representing an important opportunity to expand access to treatment on the West Coast.

Palm Beach Equine Clinic – Wellington, Florida

Led by board-certified equine surgeon Dr. Robert Brusie and his veterinary team, Palm Beach Equine Clinic is a recognized center for advanced equine medicine and surgery. The clinic is progressing through IsoPet^® certification preparations, expanding Vivos’ opportunity to serve the equine oncology market, including horses requiring treatment for solid tumors and other localized cancers.

Building a Scalable Network Through Comprehensive Certification and Training

Establishing an IsoPet^® certified veterinary facility requires a comprehensive process that extends well beyond a traditional clinic partnership. Because IsoPet^® utilizes Yttrium-90, a therapeutic radioisotope, each participating facility must meet applicable state radioactive materials licensing requirements, with regulatory review and approval timelines varying by jurisdiction.

In parallel with licensing, Vivos has implemented a structured certification and onboarding program designed to prepare veterinary teams for the safe, effective, and consistent administration of IsoPet^®. This process includes specialized radiation safety education, treatment protocol training, equipment preparation, practical application exercises, and coordinated support through the facility’s initial treatments.

While these regulatory and operational requirements take time, they are essential to establishing sustainable, revenue-generating treatment centers capable of delivering IsoPet^® consistently and safely. Each new clinic represents an investment in the Company’s long-term clinical network, with the potential to generate recurring product demand as treatment programs become established.

Vivos continues to work closely with its veterinary partners to advance each facility through the required milestones as efficiently as possible, while maintaining the standards necessary for regulatory compliance, clinical readiness, and quality patient care.

Expanding Clinical Adoption and Long-Term Commercial Opportunity

Vivos is also seeing increasing demand across its existing certified clinic network as more pet owners seek IsoPet^® treatment for their animals. This growing demand supports continued utilization at established clinics and reinforces the opportunity to expand access through new facilities.

The addition of these four facilities reflects growing interest in IsoPet^® among veterinary professionals and strengthens Vivos’ presence across multiple U.S. regions and veterinary specialties.

As participating clinics complete certification and begin treating patients, Vivos anticipates increased treatment capacity, broader geographic access, and additional opportunities for recurring IsoPet^® product sales.

With domestic IsoPet^® manufacturing capabilities established at the Company’s Applied Process Engineering Laboratory (APEL) in Richland, Washington, Vivos is building the production and clinical infrastructure necessary to support its expanding veterinary network. APEL is focused on reducing production costs to help Vivos reach break-even and advance toward profitability.

The Company’s focus remains on converting its growing clinic pipeline into fully operational treatment centers, increasing utilization across its certified network, and establishing IsoPet^® as a scalable, revenue-generating business within veterinary oncology.

The continued expansion of the IsoPet^® Animal Cancer Division supports Vivos’ broader strategy of growing commercial revenue while advancing its Precision Radionuclide Therapy^™ platform.

About Vivos Inc.

Vivos Inc. is developing advanced Yttrium-90-based Precision Radionuclide Therapy^™ (PRnT) treatments for tumors in both animals (IsoPet^®) and humans (RadioGel^®). The Company is committed to advancing targeted cancer therapies through precise, localized delivery of therapeutic radiation. IsoPet^® is commercially available for veterinary use through appropriately licensed and certified facilities in the United States.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of applicable securities laws. These statements include expectations regarding clinic certifications, regulatory approvals, future treatment activity, commercial expansion, and revenue growth. Actual results may differ materially from those expressed or implied due to regulatory timelines, operational requirements, market conditions, and other risks and uncertainties. Vivos Inc. undertakes no obligation to update forward-looking statements except as required by law.

Contact:
Vivos Inc. Investor Relations investors@vivosinc.com www.VivosInc.com

MINNEAPOLIS, Nov. 03, 2026 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

• A fireside chat at Guggenheim’s 3rd Annual Healthcare Innovation Conference at 3:00 p.m. EST on Tuesday, November 10, 2026. A live webcast will be available using this weblink.
• A fireside chat at the Stifel 2026 Healthcare Conference at 10:40 a.m. EST on Wednesday, November 11, 2026. A live webcast will be available using this weblink.
• A fireside chat at Jefferies Global Healthcare Conference in London at 9:00 am EST / 2:00 p.m. GMT on Wednesday, November 18, 2026. A live webcast will be available using this weblink.

Alternatively, the live webcasts will be accessible from the Investors section of the company’s website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after the live events.

About Celcuity

Celcuity is a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications. The company’s first FDA-approved product is REVTORPYK™ (gedatolisib), potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- locally advanced or metastatic breast cancer (“ABC”), supported FDA approval of REVTORPYK for use in patients without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of VIKTORIA-1 have been released. VIKTORIA-2 is an ongoing Phase 3 clinical trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib plus palbociclib plus fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib plus palbociclib plus letrozole as first-line treatment for patients with endocrine- sensitive HR+/HER2- ABC. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.

Contacts: 

Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com  
(763) 392-0123  
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924

Leadership appointments build on shorter installation times and improved customer satisfaction, and position Zeo for disciplined growth

NEW PORT RICHEY, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) — Zeo Energy Corp. (Nasdaq: ZEO) (“Zeo,” or the “Company”), a provider of residential solar and commercial long-duration energy-storage solutions, today announced a leadership realignment designed to strengthen execution in core residential solar business as Zeo continues expansion into commercial opportunities to support its next phase of growth.

Kallen Konen has been promoted to Vice President of Operations, with responsibility for day-to-day execution across Zeo’s Sunergy residential solar business. Kalen Larsen, a founding partner at Zeo, has served as Chief Operating Officer since the Company’s Nasdaq listing in March 2024, will transition to a new role supporting Marketing & Operations Strategy. Both appointments are effective immediately.

Zeo has also promoted sales leader Charles Ellis to hold the position of Senior VP of Sales, and former sales manager Ty Easton to be a VP of Sales.

As Vice President of Operations, Konen will oversee installation, project management, permitting and customer fulfillment. Her priorities will include sustaining improvements in installation timelines and customer satisfaction, strengthening accountability across these functions and improving coordination from sale through installation. Konen most recently served as Zeo’s Director of People Operations.

“We are seeing progress in our residential solar operations, with shorter installation times and improved customer satisfaction,” said Tim Bridgewater, Chief Executive Officer of Zeo Energy. “Kallen Konen brings process engineering, operational experience and people leadership we need to build on that momentum. She understands how to establish clear accountability, remove bottlenecks and equip teams to deliver. As we prepare for growth into 2027, her focus will be on making that execution more consistent across the business and delivering an even better experience for our customers.”

Konen brings extensive operational leadership experience in residential solar. Before joining Zeo, she served as an Operations Director at Blue Raven Solar, a national residential solar installer later acquired by SunPower. She subsequently joined Blue Raven Solar’s executive team, leading People & Talent strategy and execution and supporting the company’s growth across more than 20 states. Earlier in her career, Konen held engineering and leadership roles at FLSmidth, Rio Tinto and Quadra Mining.

In his new role, Larsen will report to the CEO and support Zeo’s marketing efforts and long-range operational planning across residential and commercial business opportunities. His focus will be on connecting customer acquisition and market opportunities with the operating capabilities needed to support disciplined growth.

“Kalen Larsen has helped shape and lead Sunergy’s growth and Zeo’s development as a public company, bringing valuable perspective across sales, marketing and operations,” Bridgewater continued. “His experience gives him a clear understanding of how customer demand translates into operational requirements. In his new role, he will support bringing our marketing and long-range planning closer together, helping us build on our progress in residential solar and storage while pursuing opportunities in commercial long-duration energy storage.”

Together, the appointments establish dedicated leadership for day-to-day operational execution and support for the marketing and planning efforts that support Zeo’s long-term growth.

About Zeo Energy Corp.
Zeo Energy Corp. (Nasdaq: ZEO) is a diversified clean energy company providing residential, commercial, industrial, and utility-scale solutions that cut costs and carbon emissions. Zeo operates Sunergy, a residential solar, distributed energy, and efficiency solutions business. It also operates Heliogen, a long-duration energy generation and storage business designed to deliver renewable power for high-demand applications such as data centers and other energy-intensive industries. With its vertically integrated approach, Zeo helps customers secure cost-effective, 24×7 clean energy.

Cautionary Note Regarding Forward-Looking Statements
This press release and statements of Zeo’s in connection with this press release contain or may contain “forward-looking statements within the meaning of section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Exchange Act of 1934, as amended, that are based on beliefs and assumptions and on information currently available to the Company, including regarding the Company’s involvement or potential involvement in projects. Such statements may include, but are not limited to, statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions. The words “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “explore,” “develop,” “development,” “deploy,” “deployment,” “strategy,” “future,” “likely,” “may,” “should,” “will,” and similar references to future periods may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for example, statements about the development of projects, future financial performance of the Company; the ability to effectively consolidate the assets of acquired companies and produce expected results; changes in the Company’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects, the ability to raise additional funds, and plans and objectives of management. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts, and assumptions, and involve a number of significant judgments, risks, and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing the Company’s views as of any subsequent date, and the Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws. You should not place undue reliance on these forward-looking statements. As a result of a number of known and unknown risks and uncertainties, the Company’s actual results or performance may be materially and adversely different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: (i) planned pipelines and projects may not be developed in the timelines anticipated, if at all; (ii) the outcome of any legal proceedings that may be instituted against the Company or others; (iii) the Company’s success in retaining or recruiting, or changes required in, its officers, key employees, or directors; (iv) the Company’s ability to raise additional capital and maintain the listing of its common stock and warrants on Nasdaq; (v) limited liquidity and trading of the Company’s securities; (vi) geopolitical risk and changes in applicable laws or regulations, including tariffs or trade restrictions; (vii) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (viii) operational risks, including risks associated with Zeo’s expanding business model; (ix) litigation and regulatory enforcement risks, including the diversion of management time and attention and the additional costs and demands on the Company’s resources; (x) the Company’s ability to effectively consolidate the assets of acquired companies and produce the expected results; and (xi) other risks and uncertainties, including those included under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) for the year ended December 31, 2025 and in its subsequent periodic reports and other filings with the SEC.

In light of the significant risks and uncertainties associated with forward-looking statements, you should not regard these statements as a representation or warranty by the Company, its respective directors, officers or employees or any other person that the Company will achieve its objectives and plans in any specified time frame, or at all. The forward-looking statements in this news release represent the views of the Company as of the date of this news release. Subsequent events and developments may cause that view to change. However, while the Company may elect to update these forward-looking statements at some point in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of the Company as of any date subsequent to the date of this news release.

Contact:

Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
ZEO@redchip.com